| Execution period | Financial Year ended 31st March, 2026 |
|---|
BSE filing, NSE: PRISMMEDI. Summary written from the filing by ALFA Finder's alert engine.
Prism Medico and Pharmacy Ltd: key numbers
- Share price
- ₹35.65
- Market cap
- ₹48.35 Cr
- Revenue (annual)
- ₹2.44 Cr
- Net profit (annual)
- ₹0.32 Cr
- P/E (TTM)
- -121.7×Sector 43.1×
- Promoter holding
- 29.98%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Prism Medico and Pharmacy Ltd
All →Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy intimated BSE and MSEI that its corporate website is updated and functional per Regulation 46. This is a routine compliance undertaking with no financial impact.
Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31. This is a routine filing.
Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy Limited has informed that no interest, dividend, or principal is payable on non-convertible securities for the quarter ending December 31, 2026.
Prism Medico and Pharmacy Management Change
Prism Medico and Pharmacy Limited re-appointed Davender Singh as a Non-Executive Non-Independent Director. The company also updated its statutory and secretarial auditor appointments.
Prism Medico and Pharmacy Annual General Meeting
Prism Medico and Pharmacy held its 24th Annual General Meeting on September 19, 2026, to transact ordinary and special business, including various investment approvals.
Prism Medico and Pharmacy Annual Report
Prism Medico and Pharmacy Limited has filed its Annual Report for the financial year 2025-2026 in accordance with Regulation 34 of SEBI LODR Regulations.
Other other announcement announcements
All →NIIT Learning Systems Other Announcement
NIIT Learning Systems board recommended appointing Price Waterhouse Chartered Accountants LLP as statutory auditor for five years from the 25th AGM. The incumbent S. R. Batliboi firm completes its second term.
- Execution
- Five consecutive years, from the 25th AGM (2027) until the 30th AGM (2032)
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Magson Retail & Distribution Other Announcement
Magson Retail submitted its Regulation 76 Reconciliation of Share Capital Audit Report for the quarter ended 30 September 2026. The report shows a 9,15,940 share difference between issued and listed capital, pending exchange listing approval.
Ekennis Software Service Other Announcement
Ekennis Software declared Regulation 23 related party transaction rules non-applicable for H1 FY27, as its paid-up capital and net worth are below SME thresholds. A CA certificate confirms the figures.
Shri Gang Industries and Allied Products Other Announcement
Shri Gang Industries filed its quarterly shareholding pattern dated 23 October 2026. The filing notes pledges, a warrant conversion, and a deceased promoter's shares moved to a nominee.
P N Gadgil Jewellers Other Announcement
P N Gadgil Jewellers filed a Monitoring Agency Report on its QIP proceeds for the quarter ended 30 September 2026. The agency reports no deviation from the stated objects of the Rs 7,000 million issue.